Celiac Disease and Gyneco-obstetrics Complications: Can Serum Antibodies Modulate Tissue Transglutaminase Functions and Contribute to Clinical Pattern?
Article first published online: 30 MAY 2011
© 2011 John Wiley & Sons A/S
American Journal of Reproductive Immunology
Volume 66, Issue 6, pages 476–487, December 2011
How to Cite
Sóñora, C., Muñoz, F., Del Río, N., Acosta, G., Montenegro, C., Trucco, E. and Hernández, A. (2011), Celiac Disease and Gyneco-obstetrics Complications: Can Serum Antibodies Modulate Tissue Transglutaminase Functions and Contribute to Clinical Pattern?. American Journal of Reproductive Immunology, 66: 476–487. doi: 10.1111/j.1600-0897.2011.01020.x
- Issue published online: 10 NOV 2011
- Article first published online: 30 MAY 2011
- Submitted February 22, 2011; accepted April 5, 2011.
- celiac disease and reproductive disorders;
- tissue transglutaminase
Citation Sóñora C, Muñoz F, Del Río N, Acosta G, Montenegro C, Trucco E, Hernández A. Celiac disease and gyneco-obstetrics complications: can serum antibodies modulate tissue transglutaminase functions and contribute to clinical pattern? Am J Reprod Immunol 2011; 66: 476–487
Problem Untreated celiac disease (CD) is often associated with early miscarriages, infertility, and alterations in menstrual cycle. Tissue transglutaminase (tTG) antibodies could be involved by interfering with tTG transamidating activity and/or biological functions mediated by its interaction with fibronectin (FN).
Method of study The correlation between the presence of extra-digestive disorders and the reactivity of sera against tTG-FN and its effects on tTG transamidating activity was analyzed in a group or 50 women with recently diagnosed CD.
Results Heterogeneous behavior was observed among serum samples derived from patients with different complaints, suggesting that differences in fine specificity patterns could condition clinical outcome. Sera from women with gynecological and/or obstetric problems induced significant inhibition of in vitro enzymatic activity in comparison with those without these kinds of disorders.
Conclusions The significant correlation observed between serum effects and clinical profile suggests a putative involvement of tTG-specific antibodies in gynecological and/or obstetric disorders during active CD.